Want to see ACIU full AI Analyst Report?
Top Page
AC Immune SA
(NASDAQ:ACIU)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.50
▼(-12.28% Downside)
Action:Reiterated
Date:10/01/26
The score is primarily constrained by weak financial performance—persistent losses, a 2025 revenue drop, and a return to heavy cash burn—despite low leverage on the balance sheet. Technical signals are broadly neutral with slight longer-term weakness, and valuation is not supportive due to a negative P/E and no dividend yield.
Positive Factors
ACI-7104 Phase 2 clinical progress
ACI-7104’s durable week-100 safety, tolerability and immunogenicity results provide meaningful validation for AC Immune’s Parkinson’s platform. Confirmed antibody response and cerebrospinal-fluid penetration support continued development and may improve the program’s partnering and clinical funding prospects.
Negative Factors
Persistent structural unprofitability
Persistent operating and net losses show that AC Immune has not yet achieved commercial economics or operating leverage. Because revenue remains small relative to expenses, the company’s ability to fund research and development depends on collaborations, milestones, cash reserves or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
ACI-7104 Phase 2 clinical progress
ACI-7104’s durable week-100 safety, tolerability and immunogenicity results provide meaningful validation for AC Immune’s Parkinson’s platform. Confirmed antibody response and cerebrospinal-fluid penetration support continued development and may improve the program’s partnering and clinical funding prospects.
Read all positive factors
AC Immune SA (ACIU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$254.43M
Dividend YieldN/A
Average Volume (3M)175.14K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-33.68%
EPS Growth4.48%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding101,773,575
10 Day Avg. Volume238,067
30 Day Avg. Volume175,142
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)5.58
Price to Sales (P/S)70.23
P/FCF Ratio-3.74
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue7.34
Enterprise Value/Gross Profit7.34
Enterprise Value/Ebitda-3.08
Forecast
1Y Price Target
$10.00Price Target Upside250.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$20.07M
AC Immune SA Business Overview & Revenue Model
Company Description
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding...
How the Company Makes Money
AC Immune primarily makes money through partnering and collaboration arrangements rather than product sales (it is a clinical-stage company and does not have broadly commercialized therapeutics). Key revenue streams typically include (1) upfront p...
AC Immune SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.51M | 3.57M | 27.31M | 14.80M | 3.94M | 0.00 |
| Gross Profit | 17.51M | 3.57M | -35.26M | -39.80M | 3.94M | 0.00 |
| EBITDA | -41.72M | -67.75M | -48.62M | -51.83M | -68.03M | -70.01M |
| Net Income | -43.16M | -70.45M | -50.92M | -54.23M | -70.75M | -73.00M |
Balance Sheet | ||||||
| Total Assets | 150.40M | 154.43M | 230.91M | 182.81M | 185.94M | 261.44M |
| Cash, Cash Equivalents and Short-Term Investments | 75.36M | 91.41M | 165.49M | 103.05M | 122.59M | 198.22M |
| Total Debt | 4.10M | 4.55M | 5.43M | 3.50M | 2.80M | 2.91M |
| Total Liabilities | 115.23M | 109.49M | 118.64M | 22.17M | 16.95M | 29.46M |
| Stockholders Equity | 35.17M | 44.93M | 112.27M | 160.64M | 168.99M | 231.98M |
Cash Flow | ||||||
| Free Cash Flow | -34.95M | -67.01M | 65.27M | -61.21M | -74.81M | -68.32M |
| Operating Cash Flow | -34.79M | -66.15M | 65.84M | -60.41M | -73.57M | -65.69M |
| Investing Cash Flow | 36.57M | 60.69M | -105.29M | 65.64M | 23.76M | -53.66M |
| Financing Cash Flow | -513.95K | -974.14K | -1.12M | 43.25M | -1.35M | 40.75M |
AC Immune SA Technical Analysis
Negative
2.85
Price Trends
2.62
Negative
2.54
Negative
2.80
Negative
Market Momentum
-0.03
Positive
42.81
Neutral
23.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Negative. The current price of 2.85 is above the 20-day moving average (MA) of 2.65, above the 50-day MA of 2.62, and above the 200-day MA of 2.80, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.81 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACIU.
AC Immune SA Risk Analysis
AC Immune SA disclosed 82 risk factors in its most recent earnings report. AC Immune SA reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AC Immune SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $920.85M | -2.81 | -82.68% | ― | ― | -37.48% | |
47 Neutral | $445.38M | -3.88 | -196.63% | ― | 20.83% | 73.89% | |
46 Neutral | $254.43M | -4.82 | -99.17% | ― | -33.68% | 4.48% | |
42 Neutral | $232.25M | -1.89 | -531.04% | ― | -82.91% | 6.27% | |
42 Neutral | $118.77M | -2.02 | 72.64% | ― | 51.98% | 17.68% | |
41 Neutral | $1.18B | -0.06 | -91.63% | ― | ― | 69.48% |
* Healthcare Sector Average
ACIU
AC Immune SA
2.50
-0.97
-27.95%
EDIT
Editas Medicine
2.90
-0.66
-18.54%
ALEC
Alector
2.08
-0.96
-31.58%
MLTX
MoonLake Immunotherapeutics
10.82
0.16
1.50%
FHTX
Foghorn Therapeutics
2.00
-2.29
-53.38%
VOR
Vor Biopharma
19.90
-12.39
-38.37%
AC Immune SA Corporate Events
AC Immune Adds Tom Graney to Board Following Extraordinary General Meeting
Oct 2, 2026
AC Immune SA reported that on October 2, 2026, it held an Extraordinary General Meeting at which shareholders voted on changes to the company’s governance. At the meeting, investors approved the election of Tom Graney to the Board of Directo...
AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104
Sep 23, 2026
On September 23, 2026, AC Immune reported that Part 1 of its VacSYn Phase 2 trial of ACI-7104 in early-stage Parkinson’s disease met all primary endpoints for safety, tolerability and immunogenicity through week 100, with 100% of treated pat...
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board
Sep 3, 2026
On September 2, 2026, AC Immune SA called an Extraordinary General Meeting set for October 2, 2026, as part of a broader leadership and governance reshaping following the founder’s retirement at the June AGM. The meeting invitation outlines ...
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
Aug 20, 2026
On August 20, 2026, AC Immune reported positive preliminary data from a first‑in‑human Phase 1/1b trial of ACI‑19764, its orally available, brain‑penetrant small‑molecule inhibitor of the NLRP3 inflammasome. In health...
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease
Aug 11, 2026
On August 11, 2026, AC Immune announced that the U.S. FDA granted Fast Track designation and cleared an IND for its wholly owned anti-alpha-synuclein active immunotherapy, ACI-7104, in early-stage Parkinson’s disease, enabling expansion of i...
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K
Aug 5, 2026
On August 5, 2026, AC Immune SA filed a Form 6-K in the United States, furnishing unaudited interim condensed consolidated financial statements for the six months ended June 30, 2026, along with management’s discussion and updated Articles o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.